Search Results - "Ingrasciotta, Ylenia"

1

Cover Image

Journal Article

Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction

by Ingrasciotta, Ylenia Cutroneo, Paola M Marcianò, Ilaria Giezen, Thijs Atzeni, Fabiola Trifirò, Gianluca Published in Drug safety (01.11.2018)

“...In recent years, marketing of highly innovative and costly biologics improved the management of high-burden diseases such as autoimmune diseases, cancers, and...”

2

Cover Image

Journal Article

Challenges in Post-marketing Studies of Biological Drugs in the Era of Biosimilars: A Report of the International Society for Pharmacoepidemiology 2019 Mid-Year Meeting in Rome, It...

by Ingrasciotta, Ylenia Sultana, Janet Kirchmayer, Ursula Trifirò, Gianluca Published in BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy (01.08.2019)

“...Several controversial issues related to challenges in the post-marketing studies of biological drugs, including biosimilars, were discussed at the...”

3

Journal Article

In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study

by Ylenia, I Viviana, L Ilaria, M Francesco, G Giovanni, T Graziella, A Alessano, C Ugo, T.D Domenico, S Gianluca, T Published in BMC nephrology (14.09.2019)

“...markdownabstractBACKGROUND: Evidences show that around 20% of biosimilar or originator erythropoiesis-stimulating agents (ESAs) users are hyporesponsive...”

Fulltext

4

Cover Image

Journal Article

The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?

by Trifirò, Gianluca Trifirò, Gianluca Gini, Rosa Gini, Rosa Barone-Adesi, Francesco Barone-Adesi, Francesco Beghi, Ettore Beghi, Ettore Cantarutti, Anna Cantarutti, Anna Capuano, Annalisa Capuano, Annalisa Carnovale, Carla Carnovale, Carla Clavenna, Antonio Clavenna, Antonio Dellagiovanna, Mirosa Dellagiovanna, Mirosa Ferrajolo, Carmen Ferrajolo, Carmen Franchi, Matteo Franchi, Matteo Ingrasciotta, Ylenia Ingrasciotta, Ylenia Kirchmayer, Ursula Kirchmayer, Ursula Lapi, Francesco Lapi, Francesco Leone, Roberto Leone, Roberto Leoni, Olivia Leoni, Olivia Lucenteforte, Ersilia Lucenteforte, Ersilia Moretti, Ugo Moretti, Ugo Mugelli, Alessandro Mugelli, Alessandro Naldi, Luigi Naldi, Luigi Poluzzi, Elisabetta Poluzzi, Elisabetta Rafaniello, Concita Rafaniello, Concita Rea, Federico Rea, Federico Sultana, Janet Sultana, Janet Tettamanti, Mauro Tettamanti, Mauro Traversa, Giuseppe Traversa, Giuseppe Vannacci, Alfredo Vannacci, Alfredo Mantovani, Lorenzo Mantovani, Lorenzo Corrao, Giovanni Corrao, Giovanni Published in Drug safety (07.03.2019)

“...Enormous progress has been made globally in the use of evidence derived from patients’ clinical information as they access their routine medical care. The...”

5

Cover Image

Journal Article

Direct healthcare costs of chronic kidney disease management in Italy: What cost‐savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis‐st...

by Ingrasciotta, Ylenia Sultana, Janet Formica, Dario Ientile, Valentina Aiello, Andrea Chinellato, Alessandro Tari, Daniele Ugo Gini, Rosa Pastorello, Maurizio Scondotto, Salvatore Cananzi, Pasquale Traversa, Giuseppe Rossi, Mariangela Santoro, Domenico Trifirò, Gianluca Published in Pharmacoepidemiology and drug safety (01.01.2021)

“...Purpose Erythropoiesis‐stimulating agents (ESAs), are used for treating chronic kidney disease (CKD)‐related anemia, contributing to CKD costs. The study was...”

6

Cover Image

Journal Article

Recent advances in the management of chemotherapy-induced neutropenia: biosimilar granulocyte colony-stimulating factor use in Italy

by Danova, Marco Pronzato, Paolo Ingrasciotta, Ylenia Antonuzzo, Andrea Trama, Ugo Tondini, Carlo Bernardi, Francesca Futura Published in Future oncology (London, England) (01.04.2020)

“...During the National Congress of the Italian Association of Medical Oncology, which was held in Rome, Italy, October 2019, experts met to discuss advantages of...”

7

Cover Image

Journal Article

Comparison of Direct Oral Anticoagulant Use for the Treatment of Non-Valvular Atrial Fibrillation in Pivotal Clinical Trials vs. the Real-World Setting: A Population-Based Study fr...

by Ingrasciotta, Ylenia Fontana, Andrea Mancuso, Anna Ientile, Valentina Sultana, Janet Uomo, Ilaria Pastorello, Maurizio Calabrò, Paolo Andò, Giuseppe Trifirò, Gianluca Published in Pharmaceuticals (Basel, Switzerland) (25.03.2021)

“...Patients enrolled into pivotal randomized controlled trials (RCTs) may differ substantially from those treated in a real-world (RW) setting, which may result...”

Fulltext

8

Cover Image

Journal Article

Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study

by Belleudi, Valeria Trotta, Francesco Addis, Antonio Ingrasciotta, Ylenia Ientile, Valentina Tari, Michele Gini, Rosa Pastorello, Maurizio Scondotto, Salvatore Cananzi, Pasquale Traversa, Giuseppe Davoli, Marina Trifirò, Gianluca Published in Drug safety (01.12.2019)

“...Real-world data on the comparative effectiveness and safety of switching among different epoetins (including originators and biosimilars) are limited. In light...”

Fulltext

9

Cover Image

Journal Article

Real World Use of Antidiabetic Drugs in the Years 2011-2017: A Population-Based Study from Southern Italy

by Ingrasciotta, Ylenia Bertuccio, Maria Paola Crisafulli, Salvatore Ientile, Valentina Muscianisi, Marco L'Abbate, Luca Pastorello, Maurizio Provenzano, Vincenzo Scorsone, Alessandro Scondotto, Salvatore Trifirò, Gianluca Published in International journal of environmental research and public health (18.12.2020)

“...Diabetes mellitus is a metabolic disease characterized by chronic hyperglycemia. The availability of new antidiabetic drugs (ADs) has led to complex treatment...”

Fulltext

10

Cover Image

Journal Article

Characteristics and Absolute Survival of Metastatic Colorectal Cancer Patients Treated With Biologics: A Real-World Data Analysis From Three European Countries

by Oppelt, Katja A Kuiper, Josephina G Ingrasciotta, Ylenia Ientile, Valentina Herings, Ron M C Tari, Michele Trifirò, Gianluca Haug, Ulrike Published in Frontiers in oncology (2021-00-00)

“...Biologics were approved for the treatment of advanced colorectal cancer (CRC) based on favorable benefit-risk-assessments from randomized controlled trials...”

Fulltext

11

Cover Image

Journal Article

The advent of biosimilars for the treatment of diabetes: current status and future directions

by Polimeni, Giovanni Trifirò, Gianluca Ingrasciotta, Ylenia Caputi, Achille P Published in Acta diabetologica (01.06.2015)

“...Biosimilar insulins are likely to enter the market of diabetes therapies as patents for major branded insulin products start to expire in the next few years...”

Fulltext

12

Journal Article

Correction to: In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study

by Ingrasciotta, Ylenia Lacava, Viviana Marcianò, Ilaria Giorgianni, Francesco Tripepi, Giovanni Arrigo, Graziella D’ Chinellato, Alessandro Tari, Daniele Ugo Santoro, Domenico Trifirò, Gianluca Published in BMC nephrology (09.07.2020)

“...An amendment to this paper has been published and can be accessed via the original article...”

Fulltext

13

Journal Article

In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study

by Ingrasciotta, Ylenia Belleudi, Valeria Trotta, Francesco Addis, Antonio Fontana, Andrea Chinellato, Alessandro Ientile, Valentina Tari, Daniele Ugo Roberto, Giuseppe Pastorello, Maurizio Scondotto, Salvatore Cananzi, Pasquale Traversa, Giuseppe Davoli, Marina Rossi, Mariangela Trifirò, Gianluca Published in BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy (01.02.2020)

“...Switching between different erythropoiesis-stimulating agents (ESAs) during the first year of therapy is frequent (15-20%), much more so toward reference...”

14

Cover Image

Journal Article

How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009–2013

by Ingrasciotta, Ylenia Giorgianni, Francesco Bolcato, Jenny Chinellato, Alessandro Pirolo, Roberta Tari, Daniele Ugo Troncone, Chiara Fontana, Andrea Ientile, Valentina Gini, Rosa Santoro, Domenico Santarpia, Mariacarmela Genazzani, Armando Uomo, Ilaria Pastorello, Maurizio Addario, Walter Sebastiano Pollina Scondotto, Salvatore Cananzi, Pasquale Caputi, Achille Patrizio Trifirò, Gianluca Published in BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy (01.08.2015)

“...To explore the prescription patterns of erythropoiesis-stimulating agents (ESAs) in four large Italian geographic areas, where different health policy...”

Fulltext

15

Cover Image

Journal Article

How Have Intravitreal Anti-VEGF and Dexamethasone Implant Been Used in Italy? A Multiregional, Population-Based Study in the Years 2010–2016

by Scondotto, Giulia Sultana, Janet Ientile, Valentina Ingrasciotta, Ylenia Fontana, Andrea Copetti, Massimiliano Mirabelli, Eliana Trombetta, Costantino J Rapisarda, Carlo Reibaldi, Michele Avitabile, Teresio Longo, Antonio Toro, Patricia Ibanez Vadalà, Maria Cillino, Salvatore Virgili, Gianni Gini, Rosa Leoni, Olivia Pollina Addario, Sebastiano Walter Cananzi, Pasquale La Cavera, Claudia Puzo, Maria Rosalia De Sarro, Giovambattista De Francesco, Adele Trifirò, Gianluca
edited by Thai, Khac-Minh
Published in BioMed research international (11.01.2020)

“...Purpose. To describe intravitreal anti-VEGF drug and dexamethasone use in four Italian regions. Methods. Four regional claims databases were used to measure...”

Fulltext

16

Cover Image

Journal Article

How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, f...

by Marcianò, Ilaria Ingrasciotta, Ylenia Giorgianni, Francesco Bolcato, Jenny Chinellato, Alessandro Pirolo, Roberta Di Giorgio, Annalisa Manna, Sonia Ientile, Valentina Gini, Rosa Santarpia, Mariacarmela Genazzani, Armando A Uomo, Ilaria Pastorello, Maurizio Pollina Addario, Sebastiano W Scondotto, Salvatore Cananzi, Pasquale Da Cas, Roberto Traversa, Giuseppe Rossi, Mariangela Sottosanti, Laura Caputi, Achille P Trifirò, Gianluca Published in BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy (01.08.2016)

“...Granulocyte colony-stimulating factors (G-CSFs) are biological products for which the main indication of use is chemotherapy-induced neutropenia. Biosimilars...”

17

Cover Image

Journal Article

Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009-2014

by Marcianò, Ilaria Ingrasciotta, Ylenia Giorgianni, Francesco Ientile, Valentina Chinellato, Alessandro Tari, Daniele Ugo Gini, Rosa Cannavò, Salvatore Pastorello, Maurizio Scondotto, Salvatore Cananzi, Pasquale Traversa, Giuseppe Trotta, Francesco Belleudi, Valeria Addis, Antonio Trifirò, Gianluca Published in Frontiers in endocrinology (Lausanne) (2018-00-00)

“...Somatropin [recombinant growth hormone (rGH)] is approved in children and adults for several conditions involving growth disturbances and the corresponding...”

Fulltext

18

Cover Image

Journal Article

Chronic Kidney Disease Requiring Healthcare Services: A New Approach to Evaluate Epidemiology of Renal Disease

by Trifirò, Gianluca Sultana, Janet Giorgianni, Francesco Ingrasciotta, Ylenia Buemi, Michele Muscianisi, Marco Tari, Daniele Ugo Perrotta, Margherita Canale, Valeria Arcoraci, Vincenzo Santoro, Domenico
edited by Cavagna, Lorenzo
Published in BioMed research international (20.11.2014)

“...Background. Screening-based CKD estimates may not provide a sufficient insight into the impact of CKD on the use of healthcare resources in clinical practice...”

Fulltext

19

Cover Image

Journal Article

Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: a population-based case control study

by Ingrasciotta, Ylenia Sultana, Janet Giorgianni, Francesco Fontana, Andrea Santangelo, Antonio Tari, Daniele Ugo Santoro, Domenico Arcoraci, Vincenzo Perrotta, Margherita Ibanez, Luisa Trifirò, Gianluca
edited by Seguro, Antonio Carlos
Published in PloS one (2015-00-00)

“...Non-steroidal anti-inflammatory agents (NSAIDs) are known to be associated with renal damage. No clear evidence exists regarding differential risk of chronic...”

Fulltext

20

Cover Image

Journal Article

Analgesic drug use in elderly persons: A population-based study in Southern Italy

by Ingrasciotta, Ylenia Sultana, Janet Giorgianni, Francesco Menditto, E Scuteri, Angelo Tari, Michele Giuseppe Tari, D.U Basile, G Trifirò, Gianluca
edited by Russo, Emilio
Published in PloS one (19.09.2019)

“...textabstractIntroduction Analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs), weak and strong opioids are commonly used among elderly persons...”

Fulltext

1
2
3
Next »
[3]